Following the second stage of international comparative study of drug prices conducted by the Fedreal Antimonopoly Service (FAS) of Russia under the instructions of the Russian President, the pharmaceutical manufacturers have voluntarily lowered 239 prices of drugs used for the treatment of HIV infection, tuberculosis, hepatitis B and C.
The first stage of the study, involving the international monitoring of prices for drugs purchased under 7 Nosologies Program, led to reduction of 112 prices.
The mass reduction of prices encourages the manufacturers to voluntarily lower the prices of other medicinal products, that are currently not covered by the study of the FAS of Russia, and such price reductions already amount to 27.
“As of April 4, 2017, 378 prices were reduced for medicinal products included in the list of Vital and Essential Drugs (VED) procured at the federal level. For example, in 2017, the reduction of registered prices will allow to save at least 63 million rubles of budgetary funds in the procurement of drugs for HIV infection by the Ministry of Health of Russia alone, while the price reduction for drugs included in 7 Nosologies Program will allow to save at least 5 billion rubles,” said Nadezhda Sharavskaya, Deputy Head of the Department for Control over Social Sphere and Trade, FAS of Russia.